arrow
C

Cinzia Ortega

institute for cancer research and treatment asl cn2-alba-bra
H指数:29
被引数:2,985

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the “Rebiopsy on Osi” study)

EGFR突变型非小细胞肺癌对一线奥希替尼进展:真实世界中的再活检及二线疗法的影响(“Rebiopsy on Osi”研究)

2026-07-250
OAAI
Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database

Braf突变转移性非小细胞肺癌: 来自意大利生物标志物图谱数据库的真实世界数据

2026-01-210
OAAI
Geriatric-Oncology in Italy. Where we are. A CIPOMO ( Italian College of Primary Hospital Medical Oncologists)-Gioger(Italian Group Of Geriatric Oncology) survey.

意大利老年肿瘤学现状。CIPOMO(意大利主要医院肿瘤医师学院)-Gioger(意大利老年肿瘤学组)调查。

2025-11-140
PRE
Advanced-stage ALK-positive non–small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database

晚期ALK阳性非小细胞肺癌(NSCLC)患者:来自意大利生物标志物ATLAS数据库的真实世界治疗模式与结果

2025-09-240
OAAI
Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab
2025-03-140
OAAI
Concomitant medications in patients with metastatic urothelial carcinoma receiving enfortumab vedotin: real-world data from the ARON-2EV study
2025-02-200
OAAI
Niraparib In Patients With No Residual Disease After Primary Surgery: Preliminary Results Of The MITO 40 Study

尼拉帕利在主要手术后无残留疾病患者中的应用:MITO 40研究的初步结果

2025-02-010
PRE
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?

免疫肿瘤学联合治疗的晚期肾细胞癌和中度或低风险国际转移性肾细胞癌数据库联盟标准患者的真实世界结果: 风险组的差异有效性?

2024-02-0118
PRE
Activity of cabozantinib (CABO) plus durvalumab (DURVA) in patients (pts) with advanced non-urothelial-carcinoma variant histologies (VHs) or urothelial carcinoma (UC) after platinum-based chemotherapy: Interim results from the phase II ARCADIA trial
2023-10-011
OA
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study

延长间隔给药免疫检查点抑制剂的安全性: 一项多中心队列研究

2023-04-124
OAAI
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study

验证用于透明细胞肾细胞癌的新型三维 (3D融合) 总体采样方案以克服肿瘤内异质性: Meet-Uro 18研究

2022-04-305
OAAI
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial

多西他赛和泼尼松联合或不联合恩扎鲁他胺作为转移性去势抵抗性前列腺癌患者的一线治疗: CHEIRON,一项随机II期试验

2021-09-019
PRE
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network
2021-09-015
PRE
TB and COVID-19 co-infection: rationale and aims of a global study
2021-01-0120
OA
Maintenance versus discontinuation of androgen deprivation therapy during docetaxel administration with a continuous or an intermittent schedule in metastatic, castration resistant, prostate cancer patients: A multicenter randomized phase III study of the Piemonte Oncology Network
2020-09-010
OAAI
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer
2019-12-1146
PREAI